ClinicalTrials.gg
Status unknownNCT03329495Updated Nov 6, 2017

Laparoscopic Right Hemicoloectomy for Right Colon Cancer With a Medial-to-lateral Approach Orientated by SMA or SMV

A Phase 2/3 interventional study of SMA-orientated right hemicoloectomy and SMV-orientated right hemicoloectomy in Right Colic Lymphadenopathy, sponsored by The First Affiliated Hospital with Nanjing Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

A randomized controlled clinical trial to compare the outcomes of SMA- and SMV- orientated laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach

Read the detailed description

In 2008, Germany scholar W. Hohenberger proposed the idea of complete mesocolic excision (CME) and central vascular ligation (CVL) for the standardization of colonic cancer surgery. This concept has been widely recognized and accepted. This radical operation attempts to remove the mesocolon intactly by careful dissection along the embryologic tissue planes and transection of the supplying vessels at their origin. For right-sided colon cancer, this approach involves division of the vessels at their origin from the superior mesenteric artery (SMA) and superior mesenteric vein (SMV). In our opinion, full exposure of the SMA and SMV is necessary to make sure that the origin of the colonic arteries being truly exposed and tied centrally at their origin and a maximal harvest of the regional lymphnodes. For locally advanced colon cancer, SMA- orientated surgery may be more meaningful to recerve a radical lymphadenectomy and bring benefit for their survival. However, in the traditional practise, the lymph node dissection is orientated by SMV and SMA is not exposed, tissue around SMA is left behind.

In this study, eligible patients with right colon cancer will be randomly allocated to receive either SMA- or SMV- orientated laparoscopic right hemicoloectomy. 100 patients will be enrolled in each group. In SMV- orientated surgery group, SMA is not exposed and the left boundary of resection is the left side of SMV. In SMA- orientated surgery group, the left boundary of resection is the left side of SMA and SMA is exposed.Artery sheath is not necessarily to be opened. Postoperative pathology will be analyzed with the number of lymph nodes retrieved. Postoperative recovery process and long term survival will be followed.

02

Conditions studied

  • Right Colic Lymphadenopathy

Keywords

  • right colon cancer
  • superior mesenteric artery
  • superior mesenteric vein
03

In context

Colic

127 studies on the registry are indexed under Colic; 18 are open to participants now.

This study's planned enrollment of 200 is above the median of 76 across 110 interventional studies indexed under Colic.

Browse Colic studies →

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 568 studies on the registry; 317 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suitable for curative surgery between 18 - 85 years old;
  • (ASA) grade I-III;
  • Preoperative pathological diagnosis of adenocarcinoma;
  • Tumor located at the right colon;
  • ;
  • No history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease.

Exclusion criteria

Exclusion Criteria:

  • Pregnant patient;
  • History of psychiatric disease;
  • Use of systemic ;
  • Simultaneous multiple primary colorectal cancer;
  • Preoperative enhanced CT scan of chest, abdominal and pelvic cavity shows:

    1. Tumor involves the surrounding organs and combined organ resection needed to be done;
    2. distant ;
    3. unable to perform R0 resection;
  • History of any other malignant tumor in recent 5 years;
  • Patients need emergency operation: mechanic ileus, perforation.
  • Not suitable for laparoscopic surgery (i.e., extensive adhesion caused by abdominal surgery, not suitable for artificial pneumoperitoneum, etc).
  • Conversion from laparoscopic surgery to laparotomy;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    SMA-orientated right hemicoloectomy

    SMA-orientated right hemicoloectomy

    Procedure: SMA-orientated right hemicoloectomy

  • Experimental
    SMV-orientated right hemicoloectomy

    SMV-orientated right hemicoloectomy

    Procedure: SMV-orientated right hemicoloectomy

Interventions

  • ProcedureSMA-orientated right hemicoloectomy

    Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.

  • ProcedureSMV-orientated right hemicoloectomy

    Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.

06

What researchers measure

Primary outcomes

  1. number of lymph nodes retrieved

    Time frame: 1 day

Secondary outcomes

  1. disease-free survival

    Time frame: 3 years

  2. overall survival

    Time frame: 3 years

  3. recurrence-free survival

    Time frame: 3 years

  4. early complication rate

    Early complication is defined as a complication that occurred between the finish of the surgery and postoperative day. Complications includes anastomotic leakage, anastomotic bleeding, chyle leakage, wound infection, pulmonary embolism, myocardial infarction et al.The Clavien-Dindo Classification of Surgical Complications will be applied to access the degree of severity of postoperative complications.

    Time frame: 30 days

  5. operative time

    Time frame: 1 day

07

Study locations

1 site
  • Jiangsu province hospital
    Nanjing, Jiangsu 210029, China
    • Yueming Sun · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03329495
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Jan 2018 (estimated)
Primary completion
Jan 2018 (estimated)
Completion
Jan 2023 (estimated)
Last update
Nov 6, 2017

Study contacts

Yueming Sun, PhD
Contact
jssym@vip.sina.com
02568136026
Fumin Zhang, Professor
principal investigator · Ethics Committee of the First Affiliated Hospital, Nanjing Medical University, Jiangsu Province Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion